{
    "nctId": "NCT00471159",
    "briefTitle": "A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.",
    "officialTitle": "A Randomized Phase 2 Clinical Trial Of Docetaxel With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients with confirmed advanced breast cancer.\n* Patients with HER-2 negative disease with documented disease progression after (neo)adjuvant treatment with an anthracycline-based chemotherapy regimen.\n* Patients with adequate general well-being, kidney and liver function.\n\nExclusion Criteria:\n\n* Patients that have any condition that could affect patients safety, interfere with trial results, or makes the patient inappropriate for inclusion into study.\n* Patients who have had prior chemotherapy for advanced breast cancer.\n* Patients of child-bearing potential who are unwilling to use contraception.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}